SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors monitor its tight consolidation phase, with the community debating whether the stock's relative performance against other semiconductor leaders signals a looming breakout or potential overvaluation. Market participants remain focused on the stock's critical role in global AI infrastructure and are actively analyzing volume and technical levels as they anticipate significant momentum following upcoming earnings.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging as investors cheer the semiconductor sector's broader AI momentum, heavily fueled by sympathy gains following a strong earnings report from Intel. While the community is actively debating whether this reflects sustainable demand or an overheating AI bubble, many are highlighting the rapid price expansion while navigating the volatility of a heavily shorted stock.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense buying pressure and massive trading volume as the community rallies around its role in the optical connectivity sector and potential future integration with hyperscale data centers. Investors are actively debating the company's valuation and long-term potential, with bullish sentiment driven by management's recent commentary and ongoing institutional interest.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a massive surge in market interest and investor sentiment following a significant earnings beat and strong forward guidance that surprised many who were bearish on the stock. The community is actively debating whether this movement is driven by a genuine fundamental turnaround and structural AI demand, or if it represents an overextended short squeeze that is susceptible to a sharp retracement.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending as investors digest the recent 25 million dollar direct offering and internal leadership shifts, including the strategic hire of a former Applied Materials executive to drive growth. Community discussion remains polarized, with some bulls highlighting potential breakthroughs in GAA and DRAM partnerships while critics continue to question the company's long-term commercial execution and revenue timeline.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz Inc is surging as investors react to a significant jury verdict awarding the company substantial damages in a lawsuit involving competitor Papaya Gaming. While the stock has seen extreme volatility and aggressive shorting, the community is intensely debating the potential for a major squeeze and whether the legal win provides long-term fundamental value.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is currently trending after a massive single-session surge driven by a strategic pivot toward AI-integrated data center infrastructure and strong forward revenue guidance. The community is actively debating the stock's sustainability, with some traders highlighting the potential for a long-term structural re-rating while others express caution regarding the rapid price appreciation and potential for a pullback.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as investors rally around its strategic positioning in the nuclear energy sector, bolstered by high-profile partnerships and a focus on meeting the immense electricity demands of AI data centers. The community is actively debating the company's long-term regulatory milestones and potential for future criticality, while closely monitoring technical price action and recent institutional accumulation.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The semiconductor sector remains a central point of market debate, with the SMH ETF showing significant volatility as traders weigh record-breaking momentum against concerns over AI-driven capex sustainability and geopolitical bottlenecks. Community members are actively split between capitalizing on the sector's parabolic rise and positioning for a potential correction, driven by intense speculation on whether recent gains represent structural growth or a speculative bubble.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is experiencing extreme volatility and intense community debate as investors weigh the stock's massive rally, driven by AI data center and power infrastructure narratives, against concerns over its financials and potential short-term exhaustion. While bulls highlight the company's GaN technology as a critical long-term play for AI energy efficiency, a vocal contingent of bears is actively shorting the stock, citing stretched valuations and the high probability of an equity offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children

Novo Nordisk shares are up on Friday after reporting oral semaglutide trial results in children aged 10-17 years old with type 2 diabetes.read more...

Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect?

INCY heads into Q1 earnings with a $1.23 billion revenue view, driven by Jakafi, Opzelura, rising royalties and multiple new launches contributing to revenues.

OLD National Bancorp IN Buys 38,631 Shares of Novo Nordisk A/S $NVO

OLD National Bancorp IN raised its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 317.8% during the 4th quarter, according to the company in its most recent 13F filing with the...

<ul class="summary-bullets"><li>The brokerage believes Hims &amp; Hers' recent partnership with Novo Nordisk “could mark a turning point,” easing key legal concerns.</li><li>JPMorgan sees positives in steadier GLP-1 business, progress toward peptide legalization, revenue rebound in the second half, and the potential for additional branded partnerships.</li><li>Hims &amp; Hers expanded its GLP-1 offerings on its platform to include Eli Lilly drugs, including Zepbound, Mounjaro, and Foundayo.</li></ul>Shares of Hims &amp; Hers Health (HIMS) rose about 4% in pre-market trading on Friday after a bullish brokerage note highlighted the company’s recent partnership with Novo Nordisk, boosting optimism around its expanding GLP-1 weight-loss offerings amid intensifying competition in the space.<a href="https://stocktwits.com/symbol/HIMS">HIMS shares</a> closed lower for a third consecutive session on Thursday, declining more than 9% during the sell-off.<h2 class="st-heading-2">HIMS-NOVO Partnership Removes Key Legal Overhang</h2>JPMorgan initiated coverage of Hims &amp; Hers with an ‘Overweight’ rating and a price target of $35, according to The Fly. This represents a near 25% upside from the stock’s closing price on Thursday.Analyst Cory Carpenter believes Hims &amp; Hers recent partnership with Novo Nordisk “could mark a turning point,” easing key legal concerns and positioning the company as a broader platform spanning branded, generic, and compounded offerings.In March, Novo Nordisk <a href="https://stocktwits.com/news-articles/markets/equity/hims-platform-novo-wegovy-availability-stock-focus/cZ3sTJFRIkI">teamed</a> up with Hims &amp; Hers, allowing the telehealth platform to offer FDA-approved versions of Wegovy and Ozempic at more affordable self-pay prices, while discontinuing the promotion of compounded GLP-1 drugs.This came after Novo sued Hims &amp; Hers for patent infringement after HIMS launched a $49-per-month compounded version of Wegovy, claiming it used the same active ingredient as the branded drug.<h2 class="st-heading-2">Analyst Sees Compelling Path For Upside</h2>The brokerage noted that the company has built a leading direct-to-consumer healthcare platform, serving around 2.5 million subscribers across areas such as weight loss, women’s health, erectile dysfunction, hair loss, testosterone, and an expanding presence in international markets.Carpenter stated that a steadier GLP-1 business, progress toward peptide legalization, an expected revenue rebound in the second half, and the potential for additional branded partnerships together create a “compelling catalyst path” for upside.Hims &amp; Hers also <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-lilly-zepbound-mounjaro-foundayo-novo-ceo-netflix-early-days/cZBfUtmReRh">expanded</a> its GLP-1 offerings on its platform to include Eli Lilly drugs such as Zepbound, Mounjaro, and Foundayo.However, HIMS is facing intensifying competition after Amazon expanded its GLP-1 management program through its One Medical platform, while rival telehealth platform Ro introduced major price cuts to its weight-loss membership program.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘extremely bullish’ a day earlier, while message volumes remained ‘extremely high.’One user said HIMS’ chart is intact and the stock could climb to “at least” $40.<stembedurl>https://stocktwits.com/Biofocuses/message/651242376</stembedurl>Another user noted that the short float is still high.<stembedurl>https://stocktwits.com/Hognose/message/651248357</stembedurl>The stock has shed around 17% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-ogn-stock-rising-in-pre-market-today/cZBWU3fReTp">Why Is OGN Stock Rising In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS). (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock Gets Pre-Market Boost – JPMorgan Initiation Flags ‘Turning Point’ With Novo Nordisk

JPMorgan initiated coverage of Hims & Hers with an ‘Overweight’ rating and a price target of $35, according to The Fly.

After A Rough Week, HIMS May Have Found Its Catalyst – JPMorgan Sees ‘Compelling Path

Equity

Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the most recent trading session, Novo Nordisk (NVO) closed at $38.52, indicating a -1.61% shift from the previous trading day.

Hims stock price reacts strongly to crucial FDA review

Hims & Hers (HIMS) has caught a powerful new tailwind, and the market is treating peptides as more than a short-lived headline. The immediate catalyst was the FDA's decision to hold a July 23-24...

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT's 2026 hinges on pemvidutide, with key readouts, a phase III start, and funding strategy set to shape investor sentiment.

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Altimmune bets big on pemvidutide across MASH, AUD and ALD, but with one drug driving value, upcoming trials could make or break the story.

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its valuation-or risk setbacks.

Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients

Novo Nordisk reports phase 3 data showing oral semaglutide reduced HbA1c in adolescents with type 2 diabetes and was well tolerated.read more...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

Novo Nordisk A/S

Traders are closely analyzing prescription script volume and efficacy data to determine if the oral pill winner is gaining an edge over competitors.

Market sentiment is under pressure following reports that major health insurers are hesitant to cover obesity drugs under new Medicare structure plans.

Long-term investors are aggressively adding to positions while calling for a technical breakout from the $35-$40 consolidation zone.

Bulls are highlighting the stock's low P/E ratio compared to sector peers as evidence of a significant pricing disconnect with fundamentals.

Frustrated retail traders are debating the impact of dual-listing volatility on price action when the European exchange and US market overlap.

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVO News

NVONovo Nordisk A/S